ABIONYX Pharma SA ABNX.PA · Stock Open ABIONYX Pharma SA in new tab
ABIONYX Pharma SA Analysis (ABNX.PA)
Is ABIONYX Pharma SA a good investment? ABIONYX Pharma SA (ABNX.PA) is currently trading at 1.83 EUR. Market analysts have a consensus price target of 10.50 EUR. This suggests a potential upside from current levels.
Earnings Schedule: ABIONYX Pharma SA is expected to release its next earnings report on Sept. 24, 2026. The market consensus estimate for Forward EPS is -0.28.
Investor FAQ
Does ABIONYX Pharma SA pay a dividend?
No, it does not currently pay a dividend.
What asset class is ABIONYX Pharma SA?
ABIONYX Pharma SA is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 24, 2026. The company currently has a trailing EPS of -0.16.
Company Profile
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
Community Discussion